Biodexa Pharmaceuticals Plc
BDRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -45.5% | 20.9% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -967.5% | -631.2% | -705.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,879.5% | -1,181.8% | -979.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,858% | -1,095.3% | -944.6% |
| EPS Diluted | -115,700 | -22,900 | -494,300 | -352,500 |
| % Growth | -405.2% | 95.4% | -40.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |